Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-08-14 19:04:44 ET · period of report 2026-08-13 · accession 0001649904-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-14 19:04 | 2026-08-13 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $17.62 | +56.6K | 75.8K | +294% | +$997.0K |
| DT | 2026-08-14 19:04 | 2026-08-13 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $117.38 | -75.8K | 0 | -100% | -$8.90M |
| DMT | 2026-08-14 19:04 | 2026-08-13 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $0.00 | -56.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-13 | M | A | 35,000 | $24.29 | 54,233 | D | — | — | (F1) The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. |
| 2 | Common | Common Stock | 2026-08-13 | M | A | 21,601 | $6.80 | 75,834 | D | — | — | (F1) The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. |
| 3 | Common | Common Stock | 2026-08-13 | S | D | 75,834 | $117.38 | 0 | D | — | — | (F1) The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. |
| 4 | Derivative | Stock Options (Right to Buy) | 2026-08-13 | M | D | 35,000 | $0.00 | 36,283 | D | $24.29 · — to 2030-11-09 | 35,000 Common Stock | (F1) The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. (F2) The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. |
| 5 | Derivative | Stock Options (Right to Buy) | 2026-08-13 | M | D | 21,601 | $0.00 | 0 | D | $6.80 · — to 2032-02-08 | 21,601 Common Stock | (F1) The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. (F3) The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |